Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Theranos Founder Receives 2-Year Ban From Owning Blood-Testing Lab

XTALKS VITALS NEWS

Elizabeth Holmes

Even amid the growing problems with the CMS and the company’s decision to void thousands of test results from 2014 to 2015, Holmes remained a strong defender of her company and its technology.

Tweetables from this article:

Tweet: CMS has suspended Theranos lab’s ability to bill Medicare and Medicaid  http://ctt.ec/beIQV+CMS has suspended Theranos lab’s ability to bill Medicare and Medicaid.

Tweet: Theranos’ Edison device was predicted to be innovation in blood testing http://ctt.ec/a6s2k+Theranos’ Edison device was predicted to be a major innovation in the blood testing industry.

Share this!

July 11, 2016 | by Sarah Massey, M.Sc.

The Centers for Medicare & Medicaid Services (CMS) has officially banned Theranos founder Elizabeth Holmes from owning or operating a blood testing laboratory, for a minimum two-year period. The federal health regulator has also slammed the company’s Newark, California facility with multiple penalties, including revoking the lab’s Clinical Laboratory Improvement Amendments (CLIA) certificate.

Last fall, the CMS identified multiple violations of proper laboratory practices during a routine inspection of the Newark facility. The severity of the violations prompted the CMS to take serious corrective actions.

Theranos and Holmes have fallen dramatically since promising an inexpensive, rapid and less-invasive blood testing device. Even amid the growing problems with the CMS and the company’s decision to void thousands of test results from 2014 to 2015, Holmes remained a strong defender of her company and its technology.

In addition to a monetary fine, the CMS has also suspended the Newark lab’s ability to bill Medicare and Medicaid for any hematology or laboratory services. Theranos plans to continue offering its blood testing services out of its Arizona-based laboratory.

“We accept full responsibility for the issues at our laboratory in Newark, California, and have already worked to undertake comprehensive remedial actions,” said Holmes. “Those actions include shutting down and subsequently rebuilding the Newark lab from the ground up, rebuilding quality systems, adding highly experienced leadership, personnel and experts, and implementing enhanced quality and training procedures.”



Theranos’ Edison device was predicted to be a major innovation in the blood testing industry. Using a fingerprick to collect a small amount of blood to fill the company’s proprietary “nanotainers”, the test is significantly less-invasive compared to traditional blood-draws using an intravenous needle.

In October of 2015, the Wall Street Journal reported that the company didn’t use the Edison device as often as they claimed, suggesting the technology could be less accurate than previously thought. Instead, Theranos was using traditional diagnostic devices sourced from companies like Siemens.

As Theranos just lost its partnership with Walgreens – forcing the company to close all 40 of its blood testing centers in Arizona – it’s unclear what effect the additional sanctions issued by the CMS will mean for the future of the company. “While we are disappointed by CMS’ decision, we take these matters very seriously and are committed to fully resolving all outstanding issues with CMS and to demonstrating our dedication to the highest standards of quality and compliance,” Holmes continued.


Keywords:  Theranos, Blood Test, Medicare


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News


CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.